Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579760 · ClinicalTrials.gov registry record · Phase 1
Intravitreal Aflibercept Injection for Radiation Retinopathy
A Phase 1 study of Macular Edema and Radiation Retinopathy, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT01579760 is a Phase 1 study of Macular Edema and Radiation Retinopathy that has completed, run by Washington University School of Medicine. The registered enrollment target is 9 participants, below the 179-participant average among 14 other Macular Edema trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01579760, a Phase 1 study of Macular Edema and Radiation Retinopathy, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation therapy.
Conditions Studied
Interventions
- DRUG Aflibercept every 2 months
- DRUG Aflibercept monthly
Study Locations (2)
Missouri
- Washington University School of Medicine - St Louis
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-11 |
| Est. Completion | 2019-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579760
The ClinicalTrials.gov registry entry for NCT01579760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 14 other Macular Edema trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept every 2 months is the first listed.
NCT01579760 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT01579760 about?
NCT01579760 is a clinical study titled "Intravitreal Aflibercept Injection for Radiation Retinopathy". The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation therapy.
What is the current status of trial NCT01579760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-11. Estimated completion is 2019-03-27.
What conditions does trial NCT01579760 study?
This clinical trial studies the following conditions: Macular Edema, Radiation Retinopathy.
What interventions are being tested in trial NCT01579760?
The interventions under investigation include: Aflibercept every 2 months (DRUG), Aflibercept monthly (DRUG).
Who is sponsoring clinical trial NCT01579760?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01579760 being conducted?
This trial has 2 study locations across Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.